|Pronunciation||acetylsalicylic acid //|
|Trade names||Bayer Aspirin, many others|
|Other names||2-acetoxybenzoic acid|
O-acetylsalicylic acid, Aspirin (BAN UK), Aspirin (USAN US)
|Main uses||Pain, fever, prevention of heart disease|
|By mouth, rectal, lysine acetylsalicylate may be given intravenously or intramuscularly|
|Defined daily dose||3 g (by mouth or rectum)|
1 g (by injection) for pain
1 tablet (irrespective of strength) for clot prevention
|Metabolism||Liver, (CYP2C19 and possibly CYP3A), some is also hydrolysed to salicylate in the gut wall.|
|Elimination half-life||Dose-dependent; 2 h to 3 h for low doses (100 mg or less), 15 h to 30 h for large doses.|
|Excretion||Urine (80–100%), sweat, saliva, feces|
|Chemical and physical data|
|Molar mass||180.159 g·mol−1|
|3D model (JSmol)|
|Melting point||136 °C (277 °F) |
|Boiling point||140 °C (284 °F) (decomposes)|
|Solubility in water||3g/L|
Aspirin, also known as acetylsalicylic acid (ASA), is a medication used to reduce pain, fever, or inflammation. Specific inflammatory conditions which aspirin is used to treat include Kawasaki disease, pericarditis, and rheumatic fever. Aspirin given shortly after a heart attack decreases the risk of death. Aspirin is also used long-term to help prevent further heart attacks, ischaemic strokes, and blood clots in people at high risk. It may also decrease the risk of certain types of cancer, particularly colorectal cancer. For pain or fever, effects typically begin within 30 minutes. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and works similarly to other NSAIDs but also suppresses the normal functioning of platelets.
One common side effect is an upset stomach. More significant side effects include stomach ulcers, stomach bleeding, and worsening asthma. Bleeding risk is greater among those who are older, drink alcohol, take other NSAIDs, or are on other blood thinners. Aspirin is not recommended in the last part of pregnancy. It is not generally recommended in children with infections because of the risk of Reye syndrome. High doses may result in ringing in the ears.
A precursor to aspirin found in leaves from the willow tree has been used for its health effects for at least 2,400 years. In 1853, chemist Charles Frédéric Gerhardt treated the medicine sodium salicylate with acetyl chloride to produce acetylsalicylic acid for the first time. For the next fifty years, other chemists established the chemical structure and came up with more efficient production methods.:69–75 In 1897, scientists at the Bayer company began studying acetylsalicylic acid as a less-irritating replacement medication for common salicylate medicines.:69–75 By 1899, Bayer had named it "Aspirin" and sold it around the world. Aspirin's popularity grew over the first half of the twentieth century leading to competition between many brands and formulations. The word Aspirin was Bayer's brand name; however, their rights to the trademark were lost or sold in many countries.
Aspirin is one of the most widely used medications globally, with an estimated 40,000 tonnes (44,000 tons) (50 to 120 billion pills) consumed each year. It is on the World Health Organization's List of Essential Medicines. As of 2014[update], the wholesale cost in the developing world is US$0.002 to US$0.025 per dose. As of 2015[update], the cost for a typical month of medication in the United States is less than US$25.00. It is available as a generic medication. In 2017, it was the 42nd most commonly prescribed medication in the United States, with more than 17 million prescriptions.
Aspirin is used in the treatment of a number of conditions, including fever, pain, rheumatic fever, and inflammatory conditions, such as rheumatoid arthritis, pericarditis, and Kawasaki disease. Lower doses of aspirin have also been shown to reduce the risk of death from a heart attack, or the risk of stroke in people who are at high risk or who have cardiovascular disease, but not in elderly people who are otherwise healthy. There is some evidence that aspirin is effective at preventing colorectal cancer, though the mechanisms of this effect are unclear. In the United States, low-dose aspirin is deemed reasonable in those between 50 and 70 years old who have a risk of cardiovascular disease over 10%, are not at an increased risk of bleeding, and are otherwise healthy.
Aspirin is an effective analgesic for acute pain, although it is generally considered inferior to ibuprofen because aspirin is more likely to cause gastrointestinal bleeding. Aspirin is generally ineffective for those pains caused by muscle cramps, bloating, gastric distension, or acute skin irritation. As with other NSAIDs, combinations of aspirin and caffeine provide slightly greater pain relief than aspirin alone. Effervescent formulations of aspirin relieve pain faster than aspirin in tablets, which makes them useful for the treatment of migraines. Topical aspirin may be effective for treating some types of neuropathic pain.
Aspirin, either by itself or in a combined formulation, effectively treats certain types of a headache, but its efficacy may be questionable for others. Secondary headaches, meaning those caused by another disorder or trauma, should be promptly treated by a medical provider.
Among primary headaches, the International Classification of Headache Disorders distinguishes between tension headache (the most common), migraine, and cluster headache. Aspirin or other over-the-counter analgesics are widely recognized as effective for the treatment of tension headache.
Aspirin, especially as a component of an aspirin/paracetamol/caffeine combination, is considered a first-line therapy in the treatment of migraine, and comparable to lower doses of sumatriptan. It is most effective at stopping migraines when they are first beginning.
Like its ability to control pain, aspirin's ability to control fever is due to its action on the prostaglandin system through its irreversible inhibition of COX. Although aspirin's use as an antipyretic in adults is well established, many medical societies and regulatory agencies, including the American Academy of Family Physicians, the American Academy of Pediatrics, and the Food and Drug Administration, strongly advise against using aspirin for treatment of fever in children because of the risk of Reye's syndrome, a rare but often fatal illness associated with the use of aspirin or other salicylates in children during episodes of viral or bacterial infection. Because of the risk of Reye's syndrome in children, in 1986, the US Food and Drug Administration (FDA) required labeling on all aspirin-containing medications advising against its use in children and teenagers.
Heart attacks and strokes
Aspirin is an important part of the treatment of those who have had a heart attack. It is generally not recommended for routine use by people with no other health problems, including those over the age of 70.
For people who have already had a heart attack or stroke, taking aspirin daily for two years prevented 1 in 50 from having a cardiovascular problem (heart attack, stroke, or death), but also caused non-fatal bleeding problems to occur in 1 of 400 people. Low dose aspirin appears useful for people less than 70 kg while higher dose aspirin is required to benefit those over 70 kg.
The United States Preventive Services Task Force (USPSTF), as of 2016[update], recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease and colon cancer in adults aged 50 to 59 years who have a 10% or greater 10-year cardiovascular disease (CVD) risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.
March 2009 recommendations from the USPSTF on the use of aspirin for the primary prevention of coronary heart disease encourage men aged 45–79 and women aged 55–79 to use aspirin when the potential benefit of a reduction in MI for men or stroke for women outweighs the potential harm of an increase in gastrointestinal hemorrhage.
In those with no previous history of heart disease, aspirin decreases the risk of a non-fatal myocardial infarction but increases the risk of bleeding and does not change the overall risk of death. Specifically over 5 years it decreased the risk of a cardiovascular event by 1 in 265 and increased the risk of bleeding by 1 in 210.
Aspirin appears to offer little benefit to those at lower risk of heart attack or stroke—for instance, those without a history of these events or with pre-existing disease. Some studies recommend aspirin on a case-by-case basis, while others have suggested the risks of other events, such as gastrointestinal bleeding, were enough to outweigh any potential benefit, and recommended against using aspirin for primary prevention entirely. Aspirin has also been suggested as a component of a polypill for prevention of cardiovascular disease.
Complicating the use of aspirin for prevention is the phenomenon of aspirin resistance. For people who are resistant, aspirin's efficacy is reduced. Some authors have suggested testing regimens to identify people who are resistant to aspirin.
After percutaneous coronary interventions (PCIs), such as the placement of a coronary artery stent, a U.S. Agency for Healthcare Research and Quality guideline recommends that aspirin be taken indefinitely. Frequently, aspirin is combined with an ADP receptor inhibitor, such as clopidogrel, prasugrel, or ticagrelor to prevent blood clots. This is called dual antiplatelet therapy (DAPT). United States and European Union guidelines disagree somewhat about how long, and for what indications this combined therapy should be continued after surgery. U.S. guidelines recommend DAPT for at least 12 months, while EU guidelines recommend DAPT for 6–12 months after a drug-eluting stent placement. However, they agree that aspirin be continued indefinitely after DAPT is complete.
Aspirin is thought to reduce the overall risk of both getting cancer and dying from cancer. This effect is particularly beneficial for colorectal cancer (CRC) but must be taken for at least 10–20 years to see this benefit. It may also slightly reduce the risk of endometrial cancer, breast cancer, and prostate cancer.
Some conclude the benefits are greater than the risks due to bleeding in those at average risk. Others are unclear if the benefits are greater than the risk. Given this uncertainty, the 2007 United States Preventive Services Task Force (USPSTF) guidelines on this topic recommended against the use of aspirin for prevention of CRC in people with average risk. Nine years later however, the USPSTF issued a grade B recommendation for the use of low-dose aspirin (75 to 100 mg/day) "for the primary prevention of CVD [cardiovascular disease] and CRC in adults 50 to 59 years of age who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years".
A meta-analysis through 2019 found that aspirin reduces the risk of cancer of the colorectum, esophagus, and stomach.
Aspirin is a first-line treatment for the fever and joint-pain symptoms of acute rheumatic fever. The therapy often lasts for one to two weeks, and is rarely indicated for longer periods. After fever and pain have subsided, the aspirin is no longer necessary, since it does not decrease the incidence of heart complications and residual rheumatic heart disease. Naproxen has been shown to be as effective as aspirin and less toxic, but due to the limited clinical experience, naproxen is recommended only as a second-line treatment.
Low-dose aspirin supplementation has moderate benefits when used for prevention of pre-eclampsia. This benefit is greater when started in early pregnancy. It is recommended for this purpose at a dose of 75 to 150 mg per day from the 12th to the 36th week of pregnancy. There is no evidence that aspirin prevents dementia.
For some people, aspirin does not have as strong an effect on platelets as for others, an effect known as aspirin-resistance or insensitivity. One study has suggested women are more likely to be resistant than men, and a different, aggregate study of 2,930 people found 28% were resistant. A study in 100 Italian people, though, found, of the apparent 31% aspirin-resistant subjects, only 5% were truly resistant, and the others were noncompliant. Another study of 400 healthy volunteers found no subjects who were truly resistant, but some had "pseudoresistance, reflecting delayed and reduced drug absorption".
The defined daily dose is 3 g (by mouth) or 1 g (parenteral) or 3 g (rectal) for pain treatment and 1 tablet (by mouth irrespective of tablet strength) for thrombosis preventionAdult aspirin tablets are produced in standardised sizes, which vary slightly from country to country, for example 300 mg in Britain and 325 mg (or 5 grains) in the United States. Smaller doses are based on these standards, e.g., 75 mg and 81 mg tablets. The Page Template:Fraction/styles.css must have content model "Sanitized CSS" for TemplateStyles (current model is "mirror").81-milligram (1+1⁄4-grain) tablets are commonly called "baby aspirin" or "baby-strength", because they were originally – but no longer – intended to be administered to infants and children. No medical significance occurs due to the slight difference in dosage between the 75 mg and the 81 mg tablets. The dose required for benefit appears to depend on a person's weight. For those weighing less than 70 kilograms (150 lb), low dose is effective for preventing cardiovascular disease; for patients above this weight, higher doses are required.
In general, for adults, doses are taken four times a day for fever or arthritis, with doses near the maximal daily dose used historically for the treatment of rheumatic fever. For the prevention of myocardial infarction (MI) in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.
The WHI study said regular low dose (75 or 81 mg) aspirin female users had a 25% lower risk of death from cardiovascular disease and a 14% lower risk of death from any cause. Low-dose aspirin use was also associated with a trend toward lower risk of cardiovascular events, and lower aspirin doses (75 or 81 mg/day) may optimize efficacy and safety for people requiring aspirin for long-term prevention.
In children with Kawasaki disease, aspirin is taken at dosages based on body weight, initially four times a day for up to two weeks and then at a lower dose once daily for a further six to eight weeks.
Aspirin should not be taken by people who are allergic to ibuprofen or naproxen, or who have salicylate intolerance or a more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID-precipitated bronchospasm. Owing to its effect on the stomach lining, manufacturers recommend people with peptic ulcers, mild diabetes, or gastritis seek medical advice before using aspirin. Even if none of these conditions is present, the risk of stomach bleeding is still increased when aspirin is taken with alcohol or warfarin. People with hemophilia or other bleeding tendencies should not take aspirin or other salicylates. Aspirin is known to cause hemolytic anemia in people who have the genetic disease glucose-6-phosphate dehydrogenase deficiency, particularly in large doses and depending on the severity of the disease. Use of aspirin during dengue fever is not recommended owing to increased bleeding tendency. People with kidney disease, hyperuricemia, or gout should not take aspirin because it inhibits the kidneys' ability to excrete uric acid, thus may exacerbate these conditions. Aspirin should not be given to children or adolescents to control cold or influenza symptoms, as this has been linked with Reye's syndrome.
Aspirin use has been shown to increase the risk of gastrointestinal bleeding. Although some enteric-coated formulations of aspirin are advertised as being "gentle to the stomach", in one study, enteric coating did not seem to reduce this risk. Combining aspirin with other NSAIDs has also been shown to further increase this risk. Using aspirin in combination with clopidogrel or warfarin also increases the risk of upper gastrointestinal bleeding.
Blockade of COX-1 by aspirin apparently results in the upregulation of COX-2 as part of a gastric defense and that taking COX-2 inhibitors concurrently with aspirin increases the gastric mucosal erosion. Therefore, caution should be exercised if combining aspirin with any "natural" supplements with COX-2-inhibiting properties, such as garlic extracts, curcumin, bilberry, pine bark, ginkgo, fish oil, resveratrol, genistein, quercetin, resorcinol, and others.
In addition to enteric coating, "buffering" is the other main method companies have used to try to mitigate the problem of gastrointestinal bleeding. Buffering agents are intended to work by preventing the aspirin from concentrating in the walls of the stomach, although the benefits of buffered aspirin are disputed. Almost any buffering agent used in antacids can be used; Bufferin, for example, uses magnesium oxide. Other preparations use calcium carbonate.
Taking it with vitamin C has been investigated as a method of protecting the stomach lining. Taking equal doses of vitamin C and aspirin may decrease the amount of stomach damage that occurs compared to taking aspirin alone.
Retinal vein occlusion
It is a widespread habit among eye specialists (ophthalmologists) to prescribe Aspirin as an add-on medication for patients with retinal vein occlusion (RVO), such as central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). The reason of this widespread use is the evidence of its proven effectiveness in major systemic venous thrombotic disorders, and it has been assumed that may be similarly beneficial in various types of retinal vein occlusion.
Hoewever, a large-scale investigation based on data of nearly 700 patients showed "that aspirin or other antiplatelet aggregating agents or anticoagulants adversely influence the visual outcome in patients with CRVO and hemi-CRVO, without any evidence of protective or beneficial effect". Several expert groups, including the Royal College of Ophthalmologists, recommended against the use of antithrombotic drugs (incl. Aspirin) for patients with RVO.
Reye's syndrome, a rare but severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illness or infection. From 1981 to 1997, 1207 cases of Reye's syndrome in people younger than 18 were reported to the U.S. Centers for Disease Control and Prevention. Of these, 93% reported being ill in the three weeks preceding the onset of Reye's syndrome, most commonly with a respiratory infection, chickenpox, or diarrhea. Salicylates were detectable in 81.9% of children for whom test results were reported. After the association between Reye's syndrome and aspirin was reported, and safety measures to prevent it (including a Surgeon General's warning, and changes to the labeling of aspirin-containing drugs) were implemented, aspirin taken by children declined considerably in the United States, as did the number of reported cases of Reye's syndrome; a similar decline was found in the United Kingdom after warnings against pediatric aspirin use were issued. The U.S. Food and Drug Administration now recommends aspirin (or aspirin-containing products) should not be given to anyone under the age of 12 who has a fever, and the UK National Health Service recommends children who are under 16 years of age should not take aspirin, unless it is on the advice of a doctor.
For a small number of people, taking aspirin can result in symptoms including hives, swelling, and headache. Aspirin can exacerbate symptoms among those with chronic hives, or create acute symptoms of hives. These responses can be due to allergic reactions to aspirin, or more often due to its effect of inhibiting the COX-1 enzyme. Skin reactions may also tie to systemic contraindications, seen with NSAID-precipitated bronchospasm, or those with atopy.
Other adverse effects
Aspirin can induce swelling of skin tissues in some people. In one study, angioedema appeared one to six hours after ingesting aspirin in some of the people. However, when the aspirin was taken alone, it did not cause angioedema in these people; the aspirin had been taken in combination with another NSAID-induced drug when angioedema appeared.
Aspirin causes an increased risk of cerebral microbleeds having the appearance on MRI scans of 5 to 10 mm or smaller, hypointense (dark holes) patches. Such cerebral microbleeds are important, since they often occur prior to ischemic stroke or intracerebral hemorrhage, Binswanger disease, and Alzheimer's disease.[original research?]
A study of a group with a mean dosage of aspirin of 270 mg per day estimated an average absolute risk increase in intracerebral hemorrhage (ICH) of 12 events per 10,000 persons. In comparison, the estimated absolute risk reduction in myocardial infarction was 137 events per 10,000 persons, and a reduction of 39 events per 10,000 persons in ischemic stroke. In cases where ICH already has occurred, aspirin use results in higher mortality, with a dose of about 250 mg per day resulting in a relative risk of death within three months after the ICH around 2.5 (95% confidence interval 1.3 to 4.6).
Aspirin and other NSAIDs can cause abnormally high blood levels of potassium by inducing a hyporeninemic hypoaldosteronic state via inhibition of prostaglandin synthesis; however, these agents do not typically cause hyperkalemia by themselves in the setting of normal renal function and euvolemic state.
Aspirin can cause prolonged bleeding after operations for up to 10 days. In one study, 30 of 6499 people having elective surgery required reoperations to control bleeding. Twenty had diffuse bleeding and 10 had bleeding from a site. Diffuse, but not discrete, bleeding was associated with the preoperative use of aspirin alone or in combination with other NSAIDS in 19 of the 20 diffuse bleeding people.
On 9 July 2015, the FDA toughened warnings of increased heart attack and stroke risk associated with nonsteroidal anti-inflammatory drugs (NSAID). Aspirin is an NSAID but is not affected by the new warnings.
Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, higher than normal doses are taken over a period of time. Acute overdose has a mortality rate of 2%. Chronic overdose is more commonly lethal, with a mortality rate of 25%; chronic overdose may be especially severe in children. Toxicity is managed with a number of potential treatments, including activated charcoal, intravenous dextrose and normal saline, sodium bicarbonate, and dialysis. The diagnosis of poisoning usually involves measurement of plasma salicylate, the active metabolite of aspirin, by automated spectrophotometric methods. Plasma salicylate levels in general range from 30–100 mg/l after usual therapeutic doses, 50–300 mg/l in people taking high doses and 700–1400 mg/l following acute overdose. Salicylate is also produced as a result of exposure to bismuth subsalicylate, methyl salicylate, and sodium salicylate.
Aspirin is known to interact with other drugs. For example, acetazolamide and ammonium chloride are known to enhance the intoxicating effect of salicylates, and alcohol also increases the gastrointestinal bleeding associated with these types of drugs. Aspirin is known to displace a number of drugs from protein-binding sites in the blood, including the antidiabetic drugs tolbutamide and chlorpropamide, warfarin, methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, an important part of valproate metabolism), and other NSAIDs. Corticosteroids may also reduce the concentration of aspirin. Ibuprofen can negate the antiplatelet effect of aspirin used for cardioprotection and stroke prevention. The pharmacological activity of spironolactone may be reduced by taking aspirin, and it is known to compete with penicillin G for renal tubular secretion. Aspirin may also inhibit the absorption of vitamin C.[unreliable medical source?]
Mechanism of action
Discovery of the mechanism
In 1971, British pharmacologist John Robert Vane, then employed by the Royal College of Surgeons in London, showed aspirin suppressed the production of prostaglandins and thromboxanes. For this discovery he was awarded the 1982 Nobel Prize in Physiology or Medicine, jointly with Sune Bergström and Bengt Ingemar Samuelsson.
Prostaglandins and thromboxanes
Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the cyclooxygenase (COX; officially known as prostaglandin-endoperoxide synthase, PTGS) enzyme required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the PTGS enzyme (Suicide inhibition). This makes aspirin different from other NSAIDs (such as diclofenac and ibuprofen), which are reversible inhibitors.
Low-dose aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, producing an inhibitory effect on platelet aggregation during the lifetime of the affected platelet (8–9 days). This antithrombotic property makes aspirin useful for reducing the incidence of heart attacks in people who have had a heart attack, unstable angina, ischemic stroke or transient ischemic attack. 40 mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A2 release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.
Prostaglandins, local hormones produced in the body, have diverse effects, including the transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form blood clots. Heart attacks are caused primarily by blood clots, and low doses of aspirin are seen as an effective medical intervention for acute myocardial infarction.
COX-1 and COX-2 inhibition
At least two different types of cyclooxygenases, COX-1 and COX-2, are acted on by aspirin. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. COX-2 normally produces prostanoids, most of which are proinflammatory. Aspirin-modified PTGS2 (Prostaglandin-endoperoxide synthase 2) produces lipoxins, most of which are anti-inflammatory.[verification needed] Newer NSAID drugs, COX-2 inhibitors (coxibs), have been developed to inhibit only PTGS2, with the intent to reduce the incidence of gastrointestinal side effects.
However, several COX-2 inhibitors, such as rofecoxib (Vioxx), have been withdrawn from the market, after evidence emerged that PTGS2 inhibitors increase the risk of heart attack and stroke. Endothelial cells lining the microvasculature in the body are proposed to express PTGS2, and, by selectively inhibiting PTGS2, prostaglandin production (specifically, PGI2; prostacyclin) is downregulated with respect to thromboxane levels, as PTGS1 in platelets is unaffected. Thus, the protective anticoagulative effect of PGI2 is removed, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new PTGS once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.
Furthermore, aspirin, while inhibiting the ability of COX-2 to form pro-inflammatory products such as the prostaglandins, converts this enzyme's activity from a prostaglandin-forming cyclooxygenase to a lipoxygenase-like enzyme: aspirin-treated COX-2 metabolizes a variety of polyunsaturated fatty acids to hydroperoxy products which are then further metabolized to specialized proresolving mediators such as the aspirin-triggered lipoxins, aspirin-triggered resolvins, and aspirin-triggered maresins. These mediators possess potent anti-inflammatory activity. It is proposed that this aspirin-triggered transition of COX-2 from cyclooxygenase to lipoxygenase activity and the consequential formation of specialized proresolving mediators contributes to the anti-inflammatory effects of aspirin.
Aspirin has been shown to have at least three additional modes of action. It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons. Aspirin buffers and transports the protons. When high doses are given, it may actually cause fever, owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. In addition, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion is an important step in the immune response to infection; however, evidence is insufficient to show aspirin helps to fight infection. More recent data also suggest salicylic acid and its derivatives modulate signaling through NF-κB. NF-κB, a transcription factor complex, plays a central role in many biological processes, including inflammation.
Aspirin is readily broken down in the body to salicylic acid, which itself has anti-inflammatory, antipyretic, and analgesic effects. In 2012, salicylic acid was found to activate AMP-activated protein kinase, which has been suggested as a possible explanation for some of the effects of both salicylic acid and aspirin. The acetyl portion of the aspirin molecule has its own targets. Acetylation of cellular proteins is a well-established phenomenon in the regulation of protein function at the post-translational level. Aspirin is able to acetylate several other targets in addition to COX isoenzymes. These acetylation reactions may explain many hitherto unexplained effects of aspirin.
Aspirin decomposes rapidly in solutions of ammonium acetate or the acetates, carbonates, citrates, or hydroxides of the alkali metals. It is stable in dry air, but gradually hydrolyses in contact with moisture to acetic and salicylic acids. In solution with alkalis, the hydrolysis proceeds rapidly and the clear solutions formed may consist entirely of acetate and salicylate.
Like flour mills, factories that make aspirin tablets must pay attention to how much of the powder gets into the air inside the building, because the powder-air mixture can be explosive. The National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit in the United States of 5 mg/m3 (time-weighted average). In 1989, the Occupational Safety and Health Administration (OSHA) set a legal permissible exposure limit for aspirin of 5 mg/m3, but this was vacated by the AFL-CIO v. OSHA decision in 1993.
The synthesis of aspirin is classified as an esterification reaction. Salicylic acid is treated with acetic anhydride, an acid derivative, causing a chemical reaction that turns salicylic acid's hydroxyl group into an ester group (R-OH → R-OCOCH3). This process yields aspirin and acetic acid, which is considered a byproduct of this reaction. Small amounts of sulfuric acid (and occasionally phosphoric acid) are almost always used as a catalyst. This method is commonly employed in undergraduate teaching labs.
Aspirin, an acetyl derivative of salicylic acid, is a white, crystalline, weakly acidic substance, with a melting point of 136 °C (277 °F), and a boiling point of 140 °C (284 °F). Its acid dissociation constant (pKa) is 3.5 at 25 °C (77 °F).
Polymorphism, or the ability of a substance to form more than one crystal structure, is important in the development of pharmaceutical ingredients. Many drugs receive regulatory approval for only a single crystal form or polymorph. For a long time, only one crystal structure for aspirin was known. That aspirin might have a second crystalline form was suspected since the 1960s. The elusive second polymorph was first discovered by Vishweshwar and coworkers in 2005, and fine structural details were given by Bond et al. A new crystal type was found after attempted cocrystallization of aspirin and levetiracetam from hot acetonitrile. The form II is only stable at 100 K and reverts to form I at ambient temperature. In the (unambiguous) form I, two salicylic molecules form centrosymmetric dimers through the acetyl groups with the (acidic) methyl proton to carbonyl hydrogen bonds, and in the newly claimed form II, each salicylic molecule forms the same hydrogen bonds with two neighboring molecules instead of one. With respect to the hydrogen bonds formed by the carboxylic acid groups, both polymorphs form identical dimer structures.
Acetylsalicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is quickly absorbed through the cell membrane in the acidic conditions of the stomach. The increased pH and larger surface area of the small intestine causes aspirin to be absorbed more slowly there, as more of it is ionized. Owing to the formation of concretions, aspirin is absorbed much more slowly during overdose, and plasma concentrations can continue to rise for up to 24 hours after ingestion.
About 50–80% of salicylate in the blood is bound to albumin protein, while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.1–0.2 L/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.
As much as 80% of therapeutic doses of salicylic acid is metabolized in the liver. Conjugation with glycine forms salicyluric acid, and with glucuronic acid to form two different glucuronide esters. The conjugate with the acetyl group intact is referred to as the acyl glucuronide; the deacetylated conjugate is the phenolic glucuronide. These metabolic pathways have only a limited capacity. Small amounts of salicylic acid are also hydroxylated to gentisic acid. With large salicylate doses, the kinetics switch from first-order to zero-order, as metabolic pathways become saturated and renal excretion becomes increasingly important.
Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid (10%), salicylic phenol (10%), and acyl glucuronides (5%), gentisic acid (< 1%), and 2,3-dihydroxybenzoic acid. When small doses (less than 250 mg in an adult) are ingested, all pathways proceed by first-order kinetics, with an elimination half-life of about 2.0 h to 4.5 h. When higher doses of salicylate are ingested (more than 4 g), the half-life becomes much longer (15 h to 30 h), because the biotransformation pathways concerned with the formation of salicyluric acid and salicyl phenolic glucuronide become saturated. Renal excretion of salicylic acid becomes increasingly important as the metabolic pathways become saturated, because it is extremely sensitive to changes in urinary pH. A 10- to 20-fold increase in renal clearance occurs when urine pH is increased from 5 to 8. The use of urinary alkalinization exploits this particular aspect of salicylate elimination. It was found that short-term aspirin use in therapeutic doses might precipitate reversible acute kidney injury when the patient was ill with glomerulonephritis or cirrhosis. Aspirin for some patients with chronic kidney disease and some children with congestive heart failure was contraindicated.
Medicines made from willow and other salicylate-rich plants appear in clay tablets from ancient Sumer as well as the Ebers Papyrus from ancient Egypt.:8–13 Hippocrates referred to the use of salicylic tea to reduce fevers around 400 BC, and willow bark preparations were part of the pharmacopoeia of Western medicine in classical antiquity and the Middle Ages. Willow bark extract became recognized for its specific effects on fever, pain, and inflammation in the mid-eighteenth century. By the nineteenth century, pharmacists were experimenting with and prescribing a variety of chemicals related to salicylic acid, the active component of willow extract.:46–55
In 1853, chemist Charles Frédéric Gerhardt treated sodium salicylate with acetyl chloride to produce acetylsalicylic acid for the first time;:46–48 in the second half of the nineteenth century, other academic chemists established the compound's chemical structure and devised more efficient methods of synthesis. In 1897, scientists at the drug and dye firm Bayer began investigating acetylsalicylic acid as a less-irritating replacement for standard common salicylate medicines, and identified a new way to synthesize it.:69–75 By 1899, Bayer had dubbed this drug Aspirin and was selling it around the world.:27 The word Aspirin was Bayer's brand name, rather than the generic name of the drug; however, Bayer's rights to the trademark were lost or sold in many countries. Aspirin's popularity grew over the first half of the twentieth century leading to fierce competition with the proliferation of aspirin brands and products.
Aspirin's popularity declined after the development of acetaminophen/paracetamol in 1956 and ibuprofen in 1962. In the 1960s and 1970s, John Vane and others discovered the basic mechanism of aspirin's effects,:226–231 while clinical trials and other studies from the 1960s to the 1980s established aspirin's efficacy as an anti-clotting agent that reduces the risk of clotting diseases.:247–257 The initial large studies on the use of low-dose aspirin to prevent heart attacks that were published in the 1970s and 1980s helped spur reform in clinical research ethics and guidelines for human subject research and US federal law, and are often cited as examples of clinical trials that included only men, but from which people drew general conclusions that did not hold true for women.
Aspirin sales revived considerably in the last decades of the twentieth century, and remain strong in the twenty-first with widespread use as a preventive treatment for heart attacks and strokes.:267–269
Society and culture
In the U.S. it is available for less than US$25.00 per month. In 2017, it was the 42nd most commonly prescribed medication in the United States, with more than 17 million prescriptions. In the UK it is available to buy from a pharmacy and is not expensive.
Bayer lost its trademark for Aspirin in the United States in actions taken between 1918 and 1921 because it had failed to use the name for its own product correctly and had for years allowed the use of "Aspirin" by other manufacturers without defending the intellectual property rights. Today, aspirin is a generic trademark in many countries. Aspirin, with a capital "A", remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 80 other countries, for acetylsalicylic acid in all markets, but using different packaging and physical aspects for each.
Aspirin is sometimes used in veterinary medicine as an anticoagulant or to relieve pain associated with musculoskeletal inflammation or osteoarthritis. Aspirin should only be given to animals under the direct supervision of a veterinarian, as adverse effects—including gastrointestinal issues—are common. An aspirin overdose in any species may result in salicylate poisoning, characterized by hemorrhaging, seizures, coma, and even death.
Cats and dogs
Dogs are better able to tolerate aspirin than cats are. Cats metabolize aspirin slowly because they lack the glucuronide conjugates that aid in the excretion of aspirin, making it potentially toxic if dosing is not spaced out properly. No clinical signs of toxicosis occurred when cats were given 25 mg/kg of aspirin every 48 hours for 4 weeks, but the recommended dose for relief of pain and fever and for treating blood clotting diseases in cats is 10 mg/kg every 48 hours to allow for metabolization.
- "Aspirin". Drugs.com. American Society of Health-System Pharmacists. 6 June 2016. Archived from the original on 25 April 2017. Retrieved 30 August 2016.
- "ACETYLSALICYLIC acid = ASPIRIN = ASA oral - Essential drugs". medicalguidelines.msf.org. Retrieved 25 August 2020.
- "Aspirin Use During Pregnancy". Drugs.com. 2 April 2018. Retrieved 29 December 2019.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 21 September 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 21 September 2020.
- "Zorprin, Bayer Buffered Aspirin (aspirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 7 April 2014. Retrieved 3 April 2014.
- Brayfield, A, ed. (14 January 2014). "Aspirin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 3 April 2014.
- Haynes, William M., ed. (2011). CRC Handbook of Chemistry and Physics (92nd ed.). Boca Raton, FL: CRC Press. p. 3.8. ISBN 1439855110.
- Patrignani P, Patrono C (August 2016). "Aspirin and Cancer". Journal of the American College of Cardiology. 68 (9): 967–76. doi:10.1016/j.jacc.2016.05.083. PMID 27561771.
- Jones, Alan (2015). Chemistry: An Introduction for Medical and Health Sciences. John Wiley & Sons. pp. 5–6. ISBN 978-0-470-09290-3. Unknown parameter
- Ravina, Enrique (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs. John Wiley & Sons. p. 24. ISBN 978-3-527-32669-3. Unknown parameter
- Jeffreys, Diarmuid (2008). Aspirin the remarkable story of a wonder drug. Bloomsbury Publishing USA. ISBN 978-1-59691-816-0. Archived from the original on 8 September 2017. Unknown parameter
- Dick, Brian (2018). "Hard Work and Happenstance". Distillations. Vol. 4 no. 1. Science History Institute. pp. 44–45. Retrieved 11 July 2018. Unknown parameter
- Mann, Charles C.; Plummer, Mark L. (1991). The aspirin wars : money, medicine, and 100 years of rampant competition (1st ed.). New York: Knopf. p. 27. ISBN 978-0-394-57894-1. Unknown parameter
- "Aspirin". Chemical & Engineering News. Retrieved 13 August 2007.
- Warner TD, Mitchell JA (October 2002). "Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?". Proceedings of the National Academy of Sciences of the United States of America. 99 (21): 13371–3. Bibcode:2002PNAS...9913371W. doi:10.1073/pnas.222543099. PMC 129677. PMID 12374850.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Acetylsalicylic Acid". International Drug Price Indicator Guide. Retrieved 30 August 2016.
- Hamilton, Richart (2015). Tarascon pocket pharmacopoeia (2015 deluxe lab-coat ed.). Jones & Bartlett Learning. p. 5. ISBN 978-1-284-05756-0. Unknown parameter
- "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- "Aspirin - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- "Aspirin". The American Society of Health-System Pharmacists. Archived from the original on 1 January 2011. Retrieved 3 April 2011.
- "Aspirin for reducing your risk of heart attack and stroke: know the facts". U.S. Food and Drug Administration (FDA). Archived from the original on 14 August 2012. Retrieved 26 July 2012. This article incorporates text from this source, which is in the public domain.
- "Aspirin for the prevention of cardiovascular disease". U.S. Preventive Services Task Force. Archived from the original on 11 July 2012. Retrieved 26 July 2012. This article incorporates text from this source, which is in the public domain.
- Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. (February 2012). "Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials". Archives of Internal Medicine. 172 (3): 209–16. doi:10.1001/archinternmed.2011.628. hdl:10044/1/34287. PMID 22231610.
- McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. (September 2018). "Effect of Aspirin on Disability-free Survival in the Healthy Elderly" (PDF). The New England Journal of Medicine. 379 (16): 1499–1508. doi:10.1056/NEJMoa1800722. hdl:1885/154654. PMC 6426126. PMID 30221596.
- McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. (September 2018). "Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly". The New England Journal of Medicine. 379 (16): 1509–1518. doi:10.1056/NEJMoa1805819. PMC 6289056. PMID 30221597.
- Algra AM, Rothwell PM (May 2012). "Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials". The Lancet. Oncology. 13 (5): 518–27. doi:10.1016/S1470-2045(12)70112-2. PMID 22440112.
- Bibbins-Domingo K (June 2016). "Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. 164 (12): 836–45. doi:10.7326/m16-0577. PMID 27064677. Lay summary.
- Sachs CJ (March 2005). "Oral analgesics for acute nonspecific pain". American Family Physician. 71 (5): 913–8. PMID 15768621. Archived from the original on 28 May 2014.
- Gaciong Z (June 2003). "The real dimension of analgesic activity of aspirin". Thrombosis Research. 110 (5–6): 361–4. doi:10.1016/j.thromres.2003.08.009. PMID 14592563.
- Derry CJ, Derry S, Moore RA (December 2014). "Caffeine as an analgesic adjuvant for acute pain in adults". Cochrane Database of Systematic Reviews. 2014 (12): CD009281. doi:10.1002/14651858.CD009281.pub3. PMC 6485702. PMID 25502052.
- Hersh EV, Moore PA, Ross GL (May 2000). "Over-the-counter analgesics and antipyretics: a critical assessment". Clinical Therapeutics. 22 (5): 500–48. doi:10.1016/S0149-2918(00)80043-0. PMID 10868553.
- Mett A, Tfelt-Hansen P (June 2008). "Acute migraine therapy: recent evidence from randomized comparative trials". Current Opinion in Neurology. 21 (3): 331–7. doi:10.1097/WCO.0b013e3282fee843. PMID 18451718. S2CID 44459366.
- Kingery WS (November 1997). "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes". Pain. 73 (2): 123–39. doi:10.1016/S0304-3959(97)00049-3. PMID 9415498. S2CID 10418793.
- Loder E, Rizzoli P (January 2008). "Tension-type headache". BMJ. 336 (7635): 88–92. doi:10.1136/bmj.39412.705868.AD. PMC 2190284. PMID 18187725.
- Gilmore B, Michael M (February 2011). "Treatment of acute migraine headache". American Family Physician. 83 (3): 271–80. PMID 21302868.
- Bartfai T, Conti B (March 2010). "Fever". TheScientificWorldJournal. 10: 490–503. doi:10.1100/tsw.2010.50. PMC 2850202. PMID 20305990.
- Pugliese A, Beltramo T, Torre D (October 2008). "Reye's and Reye's-like syndromes". Cell Biochemistry and Function. 26 (7): 741–6. doi:10.1002/cbf.1465. PMID 18711704.
- Beutler AI, Chesnut GT, Mattingly JC, Jamieson B (December 2009). "FPIN's Clinical Inquiries. Aspirin use in children for fever or viral syndromes". American Family Physician. 80 (12): 1472. PMID 20000310.
- "Medications Used to Treat Fever". American Academy of Pediatrics. Archived from the original on 18 February 2013. Retrieved 25 November 2012.
- "51 FR 8180" (PDF). United States Federal Register. 51 (45). 7 March 1986. Archived from the original (PDF) on 19 August 2011.
- Morris T, Stables M, Hobbs A, de Souza P, Colville-Nash P, Warner T, et al. (August 2009). "Effects of low-dose aspirin on acute inflammatory responses in humans". Journal of Immunology. 183 (3): 2089–96. doi:10.4049/jimmunol.0900477. PMID 19597002.
- National Clinical Guideline Centre (UK) (July 2013). "Myocardial infarction with ST-segment elevation: the acute management of myocardial infarction with ST-segment elevation [Internet]". NICE Clinical Guidelines (167). 17.2 Asprin. PMID 25340241. Archived from the original on 31 December 2015.
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. (2019). "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease". Journal of the American College of Cardiology. 74 (10): e177–e232. doi:10.1016/j.jacc.2019.03.010. PMID 30894318.
- Moriarty, F; Ebell, MH (23 July 2020). "A comparison of contemporary versus older studies of aspirin for primary prevention". Family practice. 37 (3): 290–296. doi:10.1093/fampra/cmz080. PMID 31751455.
- Newman, David (10 July 2011). "Aspirin to prevent cardiovascular disease in people with known heart disease or strokes". The NNT. Archived from the original on 8 December 2015. Unknown parameter
- Hall SL, Lorenc T (February 2010). "Secondary prevention of coronary artery disease". American Family Physician. 81 (3): 289–96. PMID 20112887.
- Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. (May 2009). "Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials". Lancet. 373 (9678): 1849–60. doi:10.1016/S0140-6736(09)60503-1. PMC 2715005. PMID 19482214.
- Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JF, Roncaglioni MC, et al. (August 2018). "Effects of aspirin on risks of vascular events and cancer according to body weight and dose: analysis of individual patient data from randomised trials". Lancet. 392 (10145): 387–399. doi:10.1016/S0140-6736(18)31133-4. PMC 6083400. PMID 30017552.
- "Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication". United States Preventive Services Task Force (USPSTF). April 2016. Retrieved 22 February 2019. This article incorporates text from this source, which is in the public domain.
- US Preventive Services Task Force (March 2009). "Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement". Ann. Intern. Med. 150 (6): 396–404. doi:10.7326/0003-4819-150-6-200903170-00008. PMID 19293072.
- "Aspirin: more evidence that low dose is all that is needed". Medscape CME. Retrieved 11 May 2011.
- Lip GY, Felmeden DC, Dwivedi G (December 2011). "Antiplatelet agents and anticoagulants for hypertension". Cochrane Database of Systematic Reviews (12): CD003186. doi:10.1002/14651858.CD003186.pub3. PMC 7144733. PMID 22161375.
- Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP (June 2016). "Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force". Annals of Internal Medicine (Systematic Review & Meta-Analysis). 164 (12): 804–13. doi:10.7326/M15-2113. PMID 27064410.
- Roddick, Alistair J.; Zheng, Sean L. (22 January 2019). "Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis". JAMA. 321 (3): 277–287. doi:10.1001/jama.2018.20578. PMC 6439678. PMID 30667501.
- Wolff T, Miller T, Ko S (March 2009). "Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force". Annals of Internal Medicine. 150 (6): 405–10. doi:10.7326/0003-4819-150-6-200903170-00009. PMID 19293073. S2CID 7962360.
- Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR (July 2011). "Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials". American Heart Journal. 162 (1): 115–24.e2. doi:10.1016/j.ahj.2011.04.006. PMID 21742097.
- Norris JW (September 2005). "Antiplatelet agents in secondary prevention of stroke: a perspective". Stroke. 36 (9): 2034–6. doi:10.1161/01.STR.0000177887.14339.46. PMID 16100022.
- Sleight P, Pouleur H, Zannad F (July 2006). "Benefits, challenges, and registerability of the polypill". European Heart Journal. 27 (14): 1651–6. doi:10.1093/eurheartj/ehi841. PMID 16603580.
- Wang TH, Bhatt DL, Topol EJ (March 2006). "Aspirin and clopidogrel resistance: an emerging clinical entity". European Heart Journal. 27 (6): 647–54. doi:10.1093/eurheartj/ehi684. PMID 16364973.
- Oliveira DC, Silva RF, Silva DJ, Lima VC (September 2010). "Aspirin resistance: fact or fiction?". Arquivos Brasileiros de Cardiologia. 95 (3): e91–4. doi:10.1590/S0066-782X2010001300024. PMID 20944898.
- Topçuoglu MA, Arsava EM, Ay H (February 2011). "Antiplatelet resistance in stroke". Expert Review of Neurotherapeutics. 11 (2): 251–63. doi:10.1586/ern.10.203. PMC 3086673. PMID 21306212.
- Ben-Dor I, Kleiman NS, Lev E (July 2009). "Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy". The American Journal of Cardiology. 104 (2): 227–33. doi:10.1016/j.amjcard.2009.03.022. PMID 19576352.
- National Guideline Clearinghouse (NGC). "2011 ACCF/AHA/SCAI guideline for percutaneous coronary artery intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions". United States Agency for Healthcare Research and Quality (AHRQ). Archived from the original on 13 August 2012. Retrieved 28 August 2012.
- Musumeci G, Di Lorenzo E, Valgimigli M (December 2011). "Dual antiplatelet therapy duration: what are the drivers?". Current Opinion in Cardiology. 26 Suppl 1: S4–14. doi:10.1097/01.hco.0000409959.11246.ba. PMID 22129582. S2CID 25000528.
- Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (December 2018). "ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison". J. Am. Coll. Cardiol. 72 (23 Pt A): 2915–2931. doi:10.1016/j.jacc.2018.09.057. PMID 30522654.
- Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. (September 2016). "2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J. Am. Coll. Cardiol. 68 (10): 1082–115. doi:10.1016/j.jacc.2016.03.513. PMID 27036918.
- Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. (January 2018). "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)". Eur. Heart J. 39 (3): 213–260. doi:10.1093/eurheartj/ehx419. PMID 28886622.
- Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. (January 2015). "Estimates of benefits and harms of prophylactic use of aspirin in the general population". Annals of Oncology. 26 (1): 47–57. doi:10.1093/annonc/mdu225. PMC 4269341. PMID 25096604.
- Manzano A, Pérez-Segura P (29 April 2012). "Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention?". TheScientificWorldJournal. 2012: 327341. doi:10.1100/2012/327341. PMC 3353298. PMID 22649288.
- Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. (February 2012). "Aspirin in the chemoprevention of colorectal neoplasia: an overview". Cancer Prevention Research. 5 (2): 164–78. doi:10.1158/1940-6207.CAPR-11-0391. PMC 3273592. PMID 22084361.
- Thun MJ, Jacobs EJ, Patrono C (April 2012). "The role of aspirin in cancer prevention". Nature Reviews. Clinical Oncology. 9 (5): 259–67. doi:10.1038/nrclinonc.2011.199. PMID 22473097. S2CID 3332999.
- Richman IB, Owens DK (July 2017). "Aspirin for Primary Prevention". The Medical Clinics of North America (Review). 101 (4): 713–724. doi:10.1016/j.mcna.2017.03.004. PMID 28577622.
- Verdoodt F, Friis S, Dehlendorff C, Albieri V, Kjaer SK (February 2016). "Non-steroidal anti-inflammatory drug use and risk of endometrial cancer: A systematic review and meta-analysis of observational studies". Gynecologic Oncology. 140 (2): 352–8. doi:10.1016/j.ygyno.2015.12.009. PMID 26701413.
- Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C (June 2012). "Aspirin and cancer risk: a quantitative review to 2011". Annals of Oncology. 23 (6): 1403–15. doi:10.1093/annonc/mds113. PMID 22517822.
- Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Kandala NB, et al. (September 2013). "Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews". Health Technology Assessment. 17 (43): 1–253. doi:10.3310/hta17430. PMC 4781046. PMID 24074752.
- Kim SE (2014). "The benefit-risk consideration in long-term use of alternate-day, low dose aspirin: focus on colorectal cancer prevention". Annals of Gastroenterology. 27 (1): 87–88. PMC 3959543. PMID 24714632.
- U.S. Preventive Services Task Force (March 2007). "Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement". Annals of Internal Medicine. 146 (5): 361–4. doi:10.7326/0003-4819-146-5-200703060-00008. PMID 17339621.
- Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C (May 2020). "Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019". Ann. Oncol. 31 (5): 558–568. doi:10.1016/j.annonc.2020.02.012. PMID 32272209.
The present comprehensive meta-analysis supports and further quantifies the inverse association between regular aspirin use and the risk of colorectal and other digestive tract cancers, including some rare ones. The favorable effect of aspirin increases with longer duration of use, and, for colorectal cancer, with increasing dose.
- National Heart Foundation of Australia (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand (2006). "Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review" (PDF). National Heart Foundation of Australia. pp. 33–37. Archived from the original (PDF) on 26 July 2008.
- Saxena A, Kumar RK, Gera RP, Radhakrishnan S, Mishra S, Ahmed Z (July 2008). "Consensus guidelines on pediatric acute rheumatic fever and rheumatic heart disease". Indian Pediatrics. 45 (7): 565–73. PMID 18695275.
- Hashkes PJ, Tauber T, Somekh E, Brik R, Barash J, Mukamel M, et al. (September 2003). "Naproxen as an alternative to aspirin for the treatment of arthritis of rheumatic fever: a randomized trial". The Journal of Pediatrics. 143 (3): 399–401. doi:10.1067/S0022-3476(03)00388-3. PMID 14517527.
- Rowley AH, Shulman ST (February 2010). "Pathogenesis and management of Kawasaki disease". Expert Review of Anti-Infective Therapy. 8 (2): 197–203. doi:10.1586/eri.09.109. PMC 2845298. PMID 20109049.
- Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS (October 2006). "Salicylate for the treatment of Kawasaki disease in children". Cochrane Database of Systematic Reviews (4): CD004175. doi:10.1002/14651858.CD004175.pub2. PMID 17054199.
- Duley L, Meher S, Hunter KE, Seidler AL, Askie LM (October 2019). "Antiplatelet agents for preventing pre-eclampsia and its complications". Cochrane Database of Systematic Reviews. 2019 (10). doi:10.1002/14651858.CD004659.pub3. PMC 6820858. PMID 31684684.
- Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, et al. (2012). "Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis". Fetal Diagnosis and Therapy. 31 (3): 141–6. doi:10.1159/000336662. PMID 22441437. S2CID 26372982.
- Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E (February 2017). "The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis". American Journal of Obstetrics and Gynecology. 216 (2): 110–120.e6. doi:10.1016/j.ajog.2016.09.076. PMID 27640943. S2CID 3079979.
- Veronese, N; Stubbs, B; Maggi, S; Thompson, T; Schofield, P; Muller, C; Tseng, PT; Lin, PY; Carvalho, AF; Solmi, M (August 2017). "Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis" (PDF). Journal of the American Geriatrics Society. 65 (8): 1763–1768. doi:10.1111/jgs.14883. PMC 6810633. PMID 28425093.
- Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, et al. (May 2007). "Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction". The Annals of Pharmacotherapy. 41 (5): 737–41. doi:10.1345/aph.1H621. PMID 17456544. S2CID 22245507.
- Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (January 2008). "Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis". BMJ. 336 (7637): 195–8. doi:10.1136/bmj.39430.529549.BE. PMC 2213873. PMID 18202034.
- Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F (October 2008). "Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance". Journal of Thrombosis and Haemostasis. 6 (10): 1832–4. doi:10.1111/j.1538-7836.2008.03122.x. PMID 18680540.
- Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA (January 2013). "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". Circulation (published 4 December 2012). 127 (3): 377–85. doi:10.1161/CIRCULATIONAHA.112.117283. PMC 3552520. PMID 23212718. Lay summary (4 December 2012). Unknown parameter
- "Invention of the safety cap". digitaldukemed.mc.duke.edu. Archived from the original on 4 March 2016. Retrieved 4 September 2015.
- Rothwell, PM; Cook, NR; Gaziano, JM; Price, JF; Belch, JFF; Roncaglioni, MC; Morimoto, T; Mehta, Z (4 August 2018). "Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials". Lancet. 392 (10145): 387–399. doi:10.1016/S0140-6736(18)31133-4. PMC 6083400. PMID 30017552.
- British National Formulary (45 ed.). British Medical Journal and Royal Pharmaceutical Society of Great Britain. 2003.
- "Aspirin monograph: dosages, etc". Medscape.com. Retrieved 11 May 2011.
- British National Formulary for Children. British Medical Journal and Royal Pharmaceutical Society. 2006.
- "Aspirin information from Drugs.com". Drugs.com. Archived from the original on 9 May 2008. Retrieved 8 May 2008.
- "Oral Aspirin information". First DataBank. Archived from the original on 18 September 2000. Retrieved 8 May 2008.
- Raithel M, Baenkler HW, Naegel A, Buchwald F, Schultis HW, Backhaus B, et al. (September 2005). "Significance of salicylate intolerance in diseases of the lower gastrointestinal tract" (PDF). Journal of Physiology and Pharmacology. 56 Suppl 5 (Suppl 5): 89–102. PMID 16247191. Archived (PDF) from the original on 9 April 2011.
- Senna GE, Andri G, Dama AR, Mezzelani P, Andri L (1995). "Tolerability of imidazole salycilate in aspirin-sensitive patients". Allergy Proceedings. 16 (5): 251–4. doi:10.2500/108854195778702675. PMID 8566739.
- "PDR guide to over the counter (OTC) drugs". Archived from the original on 10 April 2008. Retrieved 28 April 2008.
- Livingstone, Frank B (1985). Frequencies of hemoglobin variants: thalassemia, the glucose-6-phosphate dehydrogenase deficiency, G6PD variants, and ovalocytosis in human populations. Oxford University Press. ISBN 978-0-19-503634-3. Unknown parameter
- "Dengue and dengue hemorrhagic fever: information for health care practitioners". Archived from the original on 17 March 2008. Retrieved 28 April 2008.
- Macdonald S (November 2002). "Aspirin use to be banned in under 16-year olds". BMJ. 325 (7371): 988c–988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.
- Sørensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. (September 2000). "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin". The American Journal of Gastroenterology. 95 (9): 2218–24. PMID 11007221.
- Delaney JA, Opatrny L, Brophy JM, Suissa S (August 2007). "Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding". CMAJ. 177 (4): 347–51. doi:10.1503/cmaj.070186. PMC 1942107. PMID 17698822.
- Wallace JL (October 2008). "Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?". Physiological Reviews. 88 (4): 1547–65. doi:10.1152/physrev.00004.2008. PMID 18923189. S2CID 448875.
- Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, del Soldato P, et al. (September 2003). "Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa". Proceedings of the National Academy of Sciences of the United States of America. 100 (19): 10937–41. Bibcode:2003PNAS..10010937F. doi:10.1073/pnas.1933204100. PMC 196906. PMID 12960371.
- "General chemistry online: FAQ: Acids and bases: What is the buffer system in buffered aspirin?". Antoine.frostburg.edu. Archived from the original on 14 April 2011. Retrieved 11 May 2011.
- Dammann HG, Saleki M, Torz M, Schulz HU, Krupp S, Schürer M, et al. (February 2004). "Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects". Alimentary Pharmacology & Therapeutics. 19 (3): 367–74. doi:10.1111/j.1365-2036.2004.01742.x. PMID 14984384.
- Konturek PC, Kania J, Hahn EG, Konturek JW (November 2006). "Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase". Journal of Physiology and Pharmacology. 57 Suppl 5 (5): 125–36. PMID 17218764.
- Hayreh SS (2014). "Ocular vascular occlusive disorders: natural history of visual outcome". Prog Retin Eye Res. 41: 1–25. doi:10.1016/j.preteyeres.2014.04.001. PMC 4073304. PMID 24769221.
- Ageno W, Beyer-Westendorf J, Garcia DA, Lazo-Langner A, McBane RD, Paciaroni M (2016). "Guidance for the management of venous thrombosis in unusual sites". J Thromb Thrombolysis. 41 (1): 129–43. doi:10.1007/s11239-015-1308-1. PMC 4715841. PMID 26780742.CS1 maint: multiple names: authors list (link)
- Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL (May 2003). "Salicylate induces tinnitus through activation of cochlear NMDA receptors". The Journal of Neuroscience. 23 (9): 3944–52. doi:10.1523/JNEUROSCI.23-09-03944.2003. PMC 6742173. PMID 12736364.
- Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB (May 1999). "Reye's syndrome in the United States from 1981 through 1997". The New England Journal of Medicine. 340 (18): 1377–82. doi:10.1056/NEJM199905063401801. PMID 10228187.
- "Reye's syndrome". NHS Choices. National Health Service. 12 January 2016.
- "Are You Sensitive to Aspirin? Here are Some Reasons Why". Health Essentials from Cleveland Clinic. 5 February 2015. Retrieved 5 March 2020.
- Doña, Inmaculada; Barrionuevo, Esther; Salas, María; Laguna, José Julio; Agúndez, José; García-Martín, Elena; Bogas, Gádor; Perkins, James Richard; Cornejo-García, José Antonio; Torres, María José (12 November 2018). "NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs". Scientific Reports. 8 (1): 16710. Bibcode:2018NatSR...816710D. doi:10.1038/s41598-018-34668-1. ISSN 2045-2322. PMC 6232098. PMID 30420763.
- Kowalski, Marek L.; Agache, Ioana; Bavbek, Sevim; Bakirtas, Arzu; Blanca, Miguel; Bochenek, Grażyna; Bonini, Matteo; Heffler, Enrico; Klimek, Ludger; Laidlaw, Tanya M.; Mullol, Joaquim (2019). "Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)—a EAACI position paper". Allergy. 74 (1): 28–39. doi:10.1111/all.13599. ISSN 1398-9995. PMID 30216468. S2CID 52276808.
- Sánchez-Borges, M.; Capriles-Hulett, A. (January 2000). "Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity". Annals of Allergy, Asthma & Immunology. 84 (1): 101–106. doi:10.1016/S1081-1206(10)62748-2. ISSN 1081-1206. PMID 10674573.
- Stadelmann WK, Digenis AG, Tobin GR (August 1998). "Impediments to wound healing". American Journal of Surgery. 176 (2A Suppl): 39S–47S. doi:10.1016/S0002-9610(98)00184-6. PMID 9777971.
- Maessen-Visch MB, de Roos KP (May 2014). "Dutch Venous Ulcer guideline update". Phlebology. 29 (1 suppl): 153–156. doi:10.1177/0268355514529693. PMID 24843102. S2CID 24399624.
- Berges-Gimeno MP, Stevenson DD (June 2004). "Nonsteroidal anti-inflammatory drug-induced reactions and desensitization". The Journal of Asthma. 41 (4): 375–84. doi:10.1081/JAS-120037650. PMID 15281324. S2CID 29909460.
- Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. (June 2009). "Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study". Archives of Neurology. 66 (6): 714–20. doi:10.1001/archneurol.2009.42. PMID 19364926.
- Gorelick PB (June 2009). "Cerebral microbleeds: evidence of heightened risk associated with aspirin use". Archives of Neurology. 66 (6): 691–3. doi:10.1001/archneurol.2009.85. PMID 19506128.
- He J, Whelton PK, Vu B, Klag MJ (December 1998). "Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials". JAMA. 280 (22): 1930–5. doi:10.1001/jama.280.22.1930. PMID 9851479. S2CID 22997730.
- Saloheimo P, Ahonen M, Juvela S, Pyhtinen J, Savolainen ER, Hillbom M (January 2006). "Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death". Stroke. 37 (1): 129–33. doi:10.1161/01.STR.0000196991.03618.31. PMID 16322483.
- Medical knowledge self-assessment program for students 4, By American College of Physicians, Clerkship Directors in Internal Medicine, Nephrology 227, Item 29
- Scher KS (January 1996). "Unplanned reoperation for bleeding". The American Surgeon. 62 (1): 52–5. PMID 8540646.
- "FDA strengthens warning of heart attack and stroke risk for non-steroidal anti-inflammatory drugs". FDA. 9 July 2015. Archived from the original on 11 July 2015. Retrieved 9 July 2015.
- Kreplick LW (2001). "Salicylate toxicity in emergency medicine". Medscape. Archived from the original on 31 August 2012.
- Gaudreault P, Temple AR, Lovejoy FH (October 1982). "The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison". Pediatrics. 70 (4): 566–9. PMID 7122154. (primary source)
- Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2242. ISBN 978-0-323-02845-5. Unknown parameter
- Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA (September 1996). "Serum concentrations of salicylic acid following topically applied salicylate derivatives". The Annals of Pharmacotherapy. 30 (9): 935–40. doi:10.1177/106002809603000903. PMID 8876850. S2CID 9843820.
- Baselt R (2011). Disposition of toxic drugs and chemicals in man (9th ed.). Seal Beach, California: Biomedical Publications. pp. 20–23. ISBN 978-0-9626523-8-7.
- "Information for Healthcare Professionals: Concomitant Use of Ibuprofen and Aspirin". FDA. U.S. Department of Health & Human Services. September 2006. Archived from the original on 19 October 2010. Retrieved 22 November 2010.
- Katzung BG (1998). Basic and clinical pharmacology. McGraw-Hill. p. 584. ISBN 978-0-8385-0565-6.
- Loh HS, Watters K, Wilson CW (1 November 1973). "The effects of aspirin on the metabolic availability of ascorbic acid in human beings". Journal of Clinical Pharmacology. 13 (11): 480–6. doi:10.1002/j.1552-4604.1973.tb00203.x. PMID 4490672.
- Basu TK (1982). "Vitamin C-aspirin interactions". International Journal for Vitamin and Nutrition Research. Supplement = Internationale Zeitschrift Fur Vitamin- und Ernahrungsforschung. Supplement. 23: 83–90. PMID 6811490.
- Ioannides C, Stone AN, Breacker PJ, Basu TK (December 1982). "Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigs". Biochemical Pharmacology. 31 (24): 4035–8. doi:10.1016/0006-2952(82)90652-9. PMID 6818974.
- Vane JR (June 1971). "Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs". Nature. 231 (25): 232–5. doi:10.1038/newbio231232a0. PMID 5284360.
- Vane JR, Botting RM (June 2003). "The mechanism of action of aspirin" (PDF). Thrombosis Research. 110 (5–6): 255–8. doi:10.1016/S0049-3848(03)00379-7. PMID 14592543. Archived (PDF) from the original on 28 February 2008.
- "The Nobel Prize in Physiology or Medicine 1982". Nobelprize.org. Archived from the original on 27 June 2017.
- "Aspirin in heart attack and stroke prevention". American Heart Association. Archived from the original on 31 March 2008. Retrieved 8 May 2008.
- Tohgi H, Konno S, Tamura K, Kimura B, Kawano K (October 1992). "Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin". Stroke. 23 (10): 1400–3. doi:10.1161/01.STR.23.10.1400. PMID 1412574.
- Goel A, Aggarwal S, Partap S, Saurabh A, Choudhary (2012). "Pharmacokinetic solubility and dissolution profile of antiarrythmic drugs". Int J Pharma Prof Res. 3 (1): 592–601.
- Martínez-González J, Badimon L (2007). "Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks". Current Pharmaceutical Design. 13 (22): 2215–27. doi:10.2174/138161207781368774. PMID 17691994.
- Funk CD, FitzGerald GA (November 2007). "COX-2 inhibitors and cardiovascular risk". Journal of Cardiovascular Pharmacology. 50 (5): 470–9. doi:10.1097/FJC.0b013e318157f72d. PMID 18030055.
- Romano M, Cianci E, Simiele F, Recchiuti A (August 2015). "Lipoxins and aspirin-triggered lipoxins in resolution of inflammation". European Journal of Pharmacology. 760: 49–63. doi:10.1016/j.ejphar.2015.03.083. PMID 25895638.
- Serhan CN, Chiang N (August 2013). "Resolution phase lipid mediators of inflammation: agonists of resolution". Current Opinion in Pharmacology. 13 (4): 632–40. doi:10.1016/j.coph.2013.05.012. PMC 3732499. PMID 23747022.
- Weylandt KH (August 2016). "Docosapentaenoic acid derived metabolites and mediators - The new world of lipid mediator medicine in a nutshell". European Journal of Pharmacology. 785: 108–115. doi:10.1016/j.ejphar.2015.11.002. PMID 26546723.
- Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, et al. (May 2000). "Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat". Alimentary Pharmacology & Therapeutics. 14 (5): 639–50. doi:10.1046/j.1365-2036.2000.00723.x. PMID 10792129.
- Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW (July 2004). "15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation". The Journal of Experimental Medicine. 200 (1): 69–78. doi:10.1084/jem.20040566. PMC 2213311. PMID 15238606. Unknown parameter
- McCarty MF, Block KI (September 2006). "Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy". Integrative Cancer Therapies. 5 (3): 252–68. doi:10.1177/1534735406291499. PMID 16880431.
- Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, et al. (May 2012). "The ancient drug salicylate directly activates AMP-activated protein kinase". Science. 336 (6083): 918–22. Bibcode:2012Sci...336..918H. doi:10.1126/science.1215327. PMC 3399766. PMID 22517326.
- Raffensperger, Lisa (19 April 2012). "Clues to aspirin's anti-cancer effects revealed". New Scientist. 214 (2862): 16. doi:10.1016/S0262-4079(12)61073-2. Archived from the original on 30 May 2015. Unknown parameter
- Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ (March 2009). "Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells". International Journal of Oncology. 34 (3): 597–608. doi:10.3892/ijo_00000185. PMID 19212664.
- Alfonso LF, Srivenugopal KS, Bhat GJ (2009). "Does aspirin acetylate multiple cellular proteins? (Review)". Molecular Medicine Reports (review). 2 (4): 533–7. doi:10.3892/mmr_00000132. PMID 21475861.
- Reynolds, E.F., ed. (1982). "Aspirin and similar analgesic and anti-inflammatory agents". Martindale: the extra pharmacopoeia (28th ed.). Rittenhouse Book Distributors. pp. 234–82. ISBN 978-0-85369-160-0.
- "Acetylsalicylic acid". NIOSH Pocket Guide to Chemical Hazards. U.S. National Institute for Occupational Safety and Health (NIOSH). 11 April 2016. Archived from the original on 11 May 2017.
- "Appendix G: 1989 Air contaminants update project – Exposure limits NOT in effect". NIOSH pocket guide to chemical hazards. National Institute for Occupational Safety and Health. 13 February 2015. Archived from the original on 18 June 2017.
- Palleros, Daniel R (2000). Experimental organic chemistry. New York: John Wiley & Sons. p. 494. ISBN 978-0-471-28250-1. Unknown parameter
- Barrans, Richard. "Aspirin aging". Newton BBS. Archived from the original on 18 May 2008. Retrieved 8 May 2008. Unknown parameter
- Carstensen JT, Attarchi F (April 1988). "Decomposition of aspirin in the solid state in the presence of limited amounts of moisture III: Effect of temperature and a possible mechanism". Journal of Pharmaceutical Sciences. 77 (4): 318–21. doi:10.1002/jps.2600770407. PMID 3379589.
- Myers, Richard Leroy (2007). The 100 most important chemical compounds: a reference guide. ABC-CLIO. p. 10. ISBN 978-0-313-33758-1. Archived from the original on 10 June 2013. Unknown parameter
- "Acetylsalicylic acid". Jinno Laboratory, School of Materials Science, Toyohashi University of Technology. 4 March 1996. Archived from the original on 20 January 2012. Retrieved 12 April 2014.
- Vishweshwar P, McMahon JA, Oliveira M, Peterson ML, Zaworotko MJ (December 2005). "The predictably elusive form II of aspirin". Journal of the American Chemical Society. 127 (48): 16802–3. doi:10.1021/ja056455b. PMID 16316223.
- Bond AD, Boese R, Desiraju GR (2007). "On the polymorphism of aspirin: crystalline aspirin as intergrowths of two "polymorphic" domains". Angewandte Chemie. 46 (4): 618–22. doi:10.1002/anie.200603373. PMID 17139692.
- Ferguson RK, Boutros AR (August 1970). "Death following self-poisoning with aspirin". JAMA. 213 (7): 1186–8. doi:10.1001/jama.213.7.1186. PMID 5468267.
- Kaufman FL, Dubansky AS (April 1972). "Darvon poisoning with delayed salicylism: a case report". Pediatrics. 49 (4): 610–1. PMID 5013423.
- Levy G, Tsuchiya T (August 1972). "Salicylate accumulation kinetics in man". The New England Journal of Medicine. 287 (9): 430–2. doi:10.1056/NEJM197208312870903. PMID 5044917.
- Grootveld M, Halliwell B (January 1988). "2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism". Biochemical Pharmacology. 37 (2): 271–80. doi:10.1016/0006-2952(88)90729-0. PMID 3342084.
- Hartwig-Otto H (November 1983). "Pharmacokinetic considerations of common analgesics and antipyretics". The American Journal of Medicine. 75 (5A): 30–7. doi:10.1016/0002-9343(83)90230-9. PMID 6606362.
- Done AK (November 1960). "Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion". Pediatrics. 26: 800–7. PMID 13723722.
- Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, et al. (2007). "Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clinical Toxicology. 45 (2): 95–131. doi:10.1080/15563650600907140. PMID 17364628.
- Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT (November 1982). "Diuresis or urinary alkalinisation for salicylate poisoning?". British Medical Journal. 285 (6352): 1383–6. doi:10.1136/bmj.285.6352.1383. PMC 1500395. PMID 6291695.
- Dargan PI, Wallace CI, Jones AL (May 2002). "An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose". Emergency Medicine Journal. 19 (3): 206–9. doi:10.1136/emj.19.3.206. PMC 1725844. PMID 11971828.
- D'Agati V (1996). "Does aspirin cause acute or chronic renal failure in experimental animals and in humans?". Am J Kidney Dis. 28 (1 Suppl 1): S24-9. doi:10.1016/s0272-6386(96)90565-x. PMID 8669425.
- Goldberg, Daniel R. (Summer 2009). "Aspirin: Turn of the Century Miracle Drug". Chemical Heritage Magazine. 27 (2): 26–30. Unknown parameter
- Schiebinger L (October 2003). "Women's health and clinical trials". The Journal of Clinical Investigation. 112 (7): 973–7. doi:10.1172/JCI19993. PMC 198535. PMID 14523031.
- "Regular aspirin intake and acute myocardial infarction". British Medical Journal. 1 (5905): 440–3. March 1974. doi:10.1136/bmj.1.5905.440. PMC 1633212. PMID 4816857.
- Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, et al. (March 1974). "A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction". British Medical Journal. 1 (5905): 436–40. doi:10.1136/bmj.1.5905.436. PMC 1633246. PMID 4593555.
- Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2019). The Top 100 Drugs: Clinical Pharmacology and Practical Prescribing (2nd ed.). Elsevier. pp. 86–88. ISBN 978-0-7020-7442-4.
- Bayer Co. v. United Drug Co., 272 F. 505, p.512 (S.D.N.Y 1921).
- CBE Style Manual Committee; Huth, Edward J. (1994). Scientific style and format: the CBE manual for authors, editors, and publishers. Cambridge University Press. p. 164. Bibcode:1994ssfc.book.....S. ISBN 978-0-521-47154-1. Archived from the original on 15 October 2015.
- "Aspirin: the versatile drug". CBC News. 28 May 2009. Archived from the original on 6 November 2016.
- Cheng TO (2007). "The history of aspirin". Texas Heart Institute Journal. 34 (3): 392–3. PMC 1995051. PMID 17948100.
- Sigma Aldrich. "Aspirin". Archived from the original on 18 August 2011. Retrieved 13 July 2009.
- British Pharmacopoeia. "Index BP 2009" (PDF). Archived from the original (PDF) on 11 April 2009. Retrieved 13 July 2009.
- Edwards, Scott H. "Nonsteroidal Anti-inflammatory Drugs: Aspirin". Merck Veterinary Manual. Archived from the original on 18 December 2016. Retrieved 20 January 2018. Unknown parameter
- "Analgesics (toxicity)". Merck. Archived from the original on 11 April 2015. Retrieved 19 January 2018.
- Lappin, Michael R, ed. (2001). Feline internal medicine secrets. Philadelphia: Hanley & Belfus. p. 160. ISBN 978-1-56053-461-7.
- "Plants poisonous to livestock". Cornell University Department of Animal Science. Archived from the original on 16 August 2015. Retrieved 3 March 2016.
|Wikimedia Commons has media related to Lua error in Module:Commons_link at line 61: attempt to index field 'wikibase' (a nil value)..|
- Ling, Greg (2005). "Aspirin". How Products are Made. 1. Thomson Gale.
Lua error in Module:Authority_control at line 1136: attempt to index field 'wikibase' (a nil value).